We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+91.05%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$582M
AUM Growth
+$269M
Cap. Flow
+$26.6M
Cap. Flow %
4.58%
Top 10 Hldgs %
97.63%
Holding
16
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SPRB
Spruce Biosciences
SPRB
+$26.6M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$284M 48.72%
3,989,412
– –
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$148M 25.39%
1,123,630
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.04B
$30.5M 5.23%
842,815
– –
SPRB
4
Spruce Biosciences
SPRB
$118M
$29.3M 5.03%
+16,073
New +$26.6M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.69B
$22.8M 3.91%
1,025,000
– –
TECX
6
Tectonic Therapeutic
TECX
$529M
$14.1M 2.42%
84,148
– –
SYRE icon
7
Spyre Therapeutics
SYRE
$8.54B
$13.3M 2.29%
67,646
– –
PSTX
8
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$11.4M 1.97%
1,043,267
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$9.33M 1.6%
1,332,485
– –
BCEL
10
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.26M 1.08%
387,653
– –
ACRS icon
11
Aclaris Therapeutics
ACRS
$726M
$4.11M 0.7%
634,455
– –
MRKR icon
12
Marker Therapeutics
MRKR
$18.8M
$2.9M 0.5%
200,000
– –
OBSV
13
DELISTED
ObsEva SA Ordinary Shares
OBSV
$2.88M 0.5%
1,386,338
– –
VIRX
14
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.01M 0.35%
288,571
– –
ZSAN
15
DELISTED
Zosano Pharma Corporation
ZSAN
$1.43M 0.25%
77,664
– –
NBRV
16
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$462K 0.08%
7,641
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Aisling Capital Management held 16 positions worth $582M, up 86% from $313M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aisling Capital Management deployed $26.6M of net new capital in Q4 2020, opening 1 new position. Its largest new stake was Spruce Biosciences: 16,073 shares worth $29.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q4 2020 buy was Spruce Biosciences: 16,073 shares worth $29.3M.
  • Aisling Capital Management's ten largest holdings make up 98% of its $582M portfolio in Q4 2020.
  • Aisling Capital Management opened 1 new position and closed 0 in Q4 2020.
  • Aisling Capital Management's portfolio value rose 86% quarter-over-quarter to $582M.

Based on Aisling Capital Management's 13F filing for Q4 2020, filed 4 Feb 2021.